association of il28b polymorphisms with the response to peginterferon plus ribavirin combined therapy in polish patients infected with hcv genotype 1 and 4

نویسندگان

krzysztof domagalski department of infectious diseases and hepatology, nicolaus copernicus university, bydgoszcz, poland; department of plant physiology and biotechnology, nicolaus copernicus university, torun, poland

małgorzata pawlowska department of infectious diseases and hepatology, nicolaus copernicus university, bydgoszcz, poland; department of infectious diseases and hepatology, nicolaus copernicus university, bydgoszcz, poland. tel/fax: +48-523255605

andrzej tretyn department of plant physiology and biotechnology, nicolaus copernicus university, torun, poland; centre for modern interdisciplinary technologies, nicolaus copernicus university, torun, poland

waldemar halota department of infectious diseases and hepatology, nicolaus copernicus university, bydgoszcz, poland

چکیده

background three single nucleotide polymorphisms (snps) near interleukin-28b (il-28b) gene were shown to be highly associated with treatment response (svr) in patients with chronic hepatitis c virus (hcv) infection. there is limited data about the role of single and combined il-28b polymorphisms in hcv-infected polish population. objectives this study's aim was to determine predictability of three il-28b gene polymorphisms and other known prognostic factors on the treatment response in hcv genotype 1 and 4 infected polish patients. the effect of il-28b polymorphisms on therapy was also compared with other known prognostic factors. patients and methods we genotyped il-28b polymorphisms (rs12979860, rs12980275 and rs8099917) by polymerase chain reaction-based restriction fragment length polymorphism assay in a group of 293 patients from which a selected cohort of 174 treatment-naïve patients underwent treatment. results we showed that rs12979860 cc [odds ratio (or) = 4.6, p < 0.001], rs12980275 aa (or = 2.9, p = 0.002) and rs8099917 tt (or = 2.2, p = 0.016) genotypes were associated with successful treatment compared to the rs12979860 ct-tt, rs12980275 ag-gg and rs8099917 tg-gg, respectively. patients bearing of il28b profile including the three favourable genotypes do not have much chance of a recovery (or = 3.4, p = 0.002). except for il-28b polymorphisms, there was no association of svr with any other pretreatment clinical data in analyzed group. the correlation of snps with other host and viral factors revealed association of favorable genotypes of il-28b markers with high levels of alanine aminotransferase and baseline hcv viral load. conclusions il-28b polymorphisms were the strongest pretreatment predictors of response to pegylated interferon and ribavirin in polish patients chronically infected with hcv genotype 1 and 4. this study confirm the strongest impact of il-28b rs12979860 on svr, nevertheless rs12980275 aa seems to be more important than rs8099917 tt in predicting positive treatment response.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

BACKGROUND Three single nucleotide polymorphisms (SNPs) near interleukin-28B (IL-28B) gene were shown to be highly associated with treatment response (SVR) in patients with chronic hepatitis C virus (HCV) infection. There is limited data about the role of single and combined IL-28B polymorphisms in HCV-infected Polish population. OBJECTIVES This study's aim was to determine predictability of ...

متن کامل

Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection

BACKGROUND Patients infected with hepatitis C virus (HCV) genotype 1 respond poorly to standard treatment with 50% or less achieving sustained virologic response. Predicting outcome is essential and could help avoid unnecessary treatment and reduce health cost. Recently, an association of amino acid substitutions in the core region and treatment outcome was observed in Japanese patients. In the...

متن کامل

Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.

OBJECTIVE Some patients with chronic hepatitis C virus (HCV) infection fail to achieve complete early virologic response (EVR) despite a marked decrease in HCV RNA at 4 weeks. We investigated the characteristics and final treatment outcomes of this patient subpopulation. METHODS A total of 516 patients with HCV genotype 1 were enrolled. Background characteristics and final outcomes were compa...

متن کامل

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients

BACKGROUND The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. The impact of baseline predictors of treatment outcome and their interplay with viral kinetics in HCV-1 CC patients has not been fully evaluated. A...

متن کامل

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

BACKGROUND & AIMS Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this patient population. METHODS This open-label, phase 3 study (HALLMARK-QUAD; NCT01573351) treated patients with chronic hepatitis C virus (HCV) genotype ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
hepatitis monthly

جلد ۱۳، شماره ۱۱، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023